Valentis
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Latest Valentis News
Apr 25, 2023
Pyxis Tankers Inc (NASDAQ:PXS) chairman and CEO Valentios (Eddie) Valentis speaks to Thomas Warner from Proactive about the impact of OPEC production cuts on Russian crude exports, the market for refined oil product tankers, the composition of the Pyxis fleet and its strategy for the future. He says Pyxis is "closely monitoring the market and asset values" for any potential opportunities.
Valentis Frequently Asked Questions (FAQ)
When was Valentis founded?
Valentis was founded in 1992.
Where is Valentis's headquarters?
Valentis's headquarters is located at 533 Airport Boulevard, Burlingame.
What is Valentis's latest funding round?
Valentis's latest funding round is PIPE - IV.
Who are the investors of Valentis?
Investors of Valentis include Xmark Opportunity Partners, Griffin Securities, Sterling Securities International, Carter Management Group, Friendly Capital Partners and 24 more.
Who are Valentis's competitors?
Competitors of Valentis include Soleno Therapeutics, Vitae Pharmaceuticals, BioCardia, Creative Biomolecules, Advanced Biohealing and 11 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Valentis to Competitors
Immunomic Therapeutics operates as a development-stage biotechnology company focusing on the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. The company develops lysosomal-associated membrane protein-based vaccines for the treatment of allergies and other human health targets. It was founded in 2005 and is based in Rockville, Maryland.
Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
Medicorp Technologies Ltd. (now merged into Matrix Laboratories) is a manufacturer of bulk drugs, including the popular Acyclovir. It also manufactures anti-viral, anti-fungal, anti-ulcer and cardiac drugs. Medicorp's core competency lies in the anti-infective, central nervous system and cardiovascular therapeutic segments. Sensing synergies between Matrix Laboratories and Medicorp in the manufacture of bulk drugs, Medicorp merged into Matrix labs.
Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.
Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
